HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade.

AbstractBACKGROUND:
Renin-angiotensin system (RAS) inhibition has proven to be helpful in reducing cardiovascular and kidney disease progression in the general population; whether kidney transplant patients would derive similar benefits is unknown. RAS inhibition also reduces posttransplantation erythrocytosis in kidney transplant recipients, but its effect on hemoglobin (Hb) levels in patients without posttransplantation erythrocytosis is unclear.
METHODS:
The Specific Management of Anemia and Hypertension in Renal Transplant (SMAhRT) recipients study was designed to examine the cardiovascular benefits of RAS blockade with telmisartan 80 mg versus placebo, and Hb management with darbepoetin α in a randomized, double-blind, single-center controlled trial in 2,000 patients over 3 years. The primary efficacy variable was a composite of all-cause mortality, myocardial infarction or stroke.
RESULTS:
The SMAhRT study was stopped prematurely due to a lower than expected event rate. At that point, 136 patients were enrolled and were followed for a mean duration of 15 months. The use of RAS blockade was not associated with an increased risk of adverse events such as worsening anemia or hyperkalemia. Likewise, the correction of Hb with darbepoetin was not associated with any increase in thrombotic events.
CONCLUSIONS:
This study provides insight into the safety of RAS inhibition and Hb correction with an erythrocyte-stimulating agent in kidney transplant recipients.
AuthorsDaniel J Salzberg, Feras F Karadsheh, Abdolreza Haririan, Venkata Reddivari, Matthew R Weir
JournalAmerican journal of nephrology (Am J Nephrol) Vol. 39 Issue 1 Pg. 1-7 ( 2014) ISSN: 1421-9670 [Electronic] Switzerland
PMID24356394 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Benzimidazoles
  • Benzoates
  • Hemoglobins
  • Erythropoietin
  • Darbepoetin alfa
  • Telmisartan
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia (complications, therapy)
  • Benzimidazoles (administration & dosage)
  • Benzoates (administration & dosage)
  • Darbepoetin alfa
  • Double-Blind Method
  • Erythropoietin (administration & dosage, analogs & derivatives)
  • Female
  • Hemoglobins (chemistry)
  • Humans
  • Hypertension (complications, therapy)
  • Kidney Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Myocardial Infarction (complications)
  • Renin-Angiotensin System (drug effects)
  • Stroke (complications)
  • Telmisartan
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: